Glucagon-Like Peptide Agonist Pipeline Drugs Insights Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight

DelveInsight's "Glucagon-Like Peptide Agonist Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Glucagon-Like Peptide Agonist pipeline landscape. It covers the Glucagon-Like Peptide Agonist Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glucagon-Like Peptide Agonist Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Glucagon-Like Peptide Agonist Pipeline? Click here to explore the therapies and trials making headlines @ Glucagon-Like Peptide Agonist Pipeline Outlook Report [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Glucagon-Like Peptide Agonist Pipeline Report

* Nov. 30, 2025, Ascletis Pharma Inc. (HKEX: 1672) announced the selection of ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR triple peptide agonist, as the company's latest clinical development candidate. This strategic milestone marks a significant advancement in Ascletis' metabolic disease pipeline. The company plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026 for ASC37 oral tablets, targeting the treatment of obesity.
* DelveInsight's Glucagon-Like Peptide Agonist Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Glucagon-Like Peptide Agonist treatment.
* The leading Glucagon-Like Peptide Agonist Companies such as Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.
* Promising Glucagon-Like Peptide Agonist Therapies such as Exenatide, NG101 , and others.

Want to know which companies are leading innovation in Glucagon-Like Peptide Agonist? Dive into the full pipeline insights @ Glucagon-Like Peptide Agonist Clinical Trials Assessment [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Glucagon-Like Peptide Agonist Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Glucagon-Like Peptide Agonist Pipeline Report also highlights the unmet needs with respect to the Glucagon-Like Peptide Agonist.

Glucagon-Like Peptide Agonist Overview

Glucagon-Like Peptide (GLP) agonists are a class of medications primarily used in the treatment of type 2 diabetes mellitus. They mimic the action of endogenous GLP-1, a hormone secreted by the intestine in response to food intake. GLP-1 plays a crucial role in regulating glucose homeostasis by stimulating insulin secretion and inhibiting glucagon release, both of which help to lower blood sugar levels. Several types of GLP-1 receptor agonists are available, each with unique formulations and dosing regimens. Exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are among the most commonly prescribed GLP-1 agonists. These medications are typically administered via subcutaneous injection, with dosing frequency ranging from once-daily to once-weekly injections. Such convenience in dosing improves patient adherence and may contribute to better treatment outcomes.

Glucagon-Like Peptide Agonist Emerging Drugs Profile

* Survodutide: Boehringer Ingelheim

Survodutide is a glucagon/GLP-1 receptor dual agonist with a novel mechanism of action that activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. Survodutide was co-invented by Boehringer Ingelheim and Zealand Pharma. Survodutide has received US FDA Fast Track Designation as well as a PRIME designation in the EU for the treatment of NASH. Survodutide is being evaluated in Phase III trials for people living with obesity, Non-alcoholic steatohepatitis, and Type 2 diabetes mellitus.

* MK-6024: Merck

MK-6024 is an investigational peptide and dual agonist at glucagon-like peptide 1 (GLP-1) and glucagon receptors in clinical development for the treatment of NASH. MK-6024 is being developed under an exclusive licensing agreement between Merck and Hanmi Pharmaceutical for the treatment of patients with NASH. The drug has been granted Fast Track Designation by the US FDA for the treatment of NASH, a more severe form of NAFLD. A Phase IIa clinical trial was conducted that compared the efficacy and safety of efinopegdutide to the GLP-1 receptor agonist semaglutide in patients with NAFLD. The results of this trial were presented at the 2023 European Association for the Study of the Liver (EASL) Annual Congress. Currently, the drug is in Phase II stage of its development for the treatment of Non-alcoholic steatohepatitis.

* TE-8105: T-E Pharma Holding

TE-8105 is an ultralong-acting human GLP-1 receptor agonist (peptide segment 7-37 of native human GLP-1), in which alanine at position 8 is replaced by 2-aminoisobutyric acid and lysine at position 26 lysine is conjugated with a fatty acid bundle containing 2 long-chain fatty acids, a C16 acid and a C18 diacid. TE-8105 has been compared with semaglutide, which is modified with one C18 diacid at 26 lysine residue, for various effects. Currently the drug is in Phase I/II stage of its clinical development for the treatment of Non-alcoholic steatohepatitis, Obesity, and Type 2 diabetes mellitus.

* CT-996: Roche

CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity. Unlike the endogenous GLP-1 hormone, CT-996 is specifically designed to be a biased GLP-1 receptor agonist that activates cAMP signaling with minimal-to-no beta-arrestin recruitment. These finely-tuned signaling properties are expected to lead to strong glycemic control, significant weight loss and good tolerability. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Obesity & Type 2 diabetes mellitus.

If you're tracking ongoing Glucagon-Like Peptide Agonist Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Glucagon-Like Peptide Agonist Treatment Drugs [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Glucagon-Like Peptide Agonist Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Glucagon-Like Peptide Agonist with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glucagon-Like Peptide Agonist Treatment.
* Glucagon-Like Peptide Agonist Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Glucagon-Like Peptide Agonist Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glucagon-Like Peptide Agonist market.

Glucagon-Like Peptide Agonist Companies

Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.

Glucagon-Like Peptide Agonist Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Glucagon-Like Peptide Agonist Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Glucagon-Like Peptide Agonist Pipeline Report covers it all - check it out now @ Glucagon-Like Peptide Agonist Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Glucagon-Like Peptide Agonist Pipeline Report

* Coverage- Global
* Glucagon-Like Peptide Agonist Companies- Sciwind, Boehringer Ingelheim, Merck, Eccogene, Suzhou Alphamab Co., Ltd., Regor Pharmaceuticals, Eli Lilly and Company, Neuraly, Carmot Therapeutics and others.
* Glucagon-Like Peptide Agonist Therapies- Exenatide, NG101 , and others.
* Glucagon-Like Peptide Agonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Glucagon-Like Peptide Agonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Glucagon-Like Peptide Agonist Treatment landscape in this detailed analysis @ Glucagon-Like Peptide Agonist Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/glucagon-like-peptide-glp-agonist-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Glucagon-Like Peptide (GLP) Agonist: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Glucagon-Like Peptide (GLP) Agonist- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Survodutide: Boehringer Ingelheim
* Mid Stage Products (Phase II)
* MK-6024: Merck
* Early Stage Products (Phase I)
* CT-996: Roche
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Inactive Products
* Glucagon-Like Peptide (GLP) Agonist Key Companies
* Glucagon-Like Peptide (GLP) Agonist Key Products
* Glucagon-Like Peptide (GLP) Agonist- Unmet Needs
* Glucagon-Like Peptide (GLP) Agonist- Market Drivers and Barriers
* Glucagon-Like Peptide (GLP) Agonist- Future Perspectives and Conclusion
* Glucagon-Like Peptide (GLP) Agonist Analyst Views
* Glucagon-Like Peptide (GLP) Agonist Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glucagonlike-peptide-agonist-pipeline-drugs-insights-report-2025-promising-drugs-and-moa-innovations-reshape-future-treatment-approaches-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glucagon-like-peptide-glp-agonist-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.